Zejing Pharmaceutical declares PD-1/TIGIT double antibody

On October 24, Zejing Pharmaceutical issued an announcement stating that its clinical trial application for ZG005 powder injection was accepted by the China Food and Drug Administration for the treatment of solid tumors

ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody powder injection.

ZG005 has a dual-targeted blocking effect on PD-1 and TIGIT, which can effectively block the signal pathway of PD-1 and its ligand PD-L1, thereby promoting the activation and proliferation of T cells; it can also effectively block TIGIT and its The signal pathways such as ligand PVR promote PVR to combine with CD226 to generate costimulatory activation signals, which in turn promote the activation and proliferation of T cells and NK cells, and produce a synergistic enhancement of the immune system to kill tumor cells after the two targets are blocked at the same time Ability

Preclinical research results show that ZG005 has a significant and long-term anti-tumor effect, and the efficacy is better than single drug (anti-PD-1 antibody or anti-TIGIT antibody) and combined administration; ZG005 has shown a drug in non-human primates Excellent pharmacokinetic characteristics and good safety characteristics in terms of half-life and so on

At present, two domestic companies have applied for the same target drug, namely Cinda Biotech and Merck, among which Merck has advanced to phase III clinical trials